Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

BUY
$16.2 - $23.18 $155,536 - $222,551
9,601 New
9,601 $206,000
Q4 2021

Feb 10, 2022

BUY
$42.59 - $55.02 $44,719 - $57,771
1,050 Added 12.28%
9,601 $428,000
Q2 2021

Aug 16, 2021

BUY
$50.3 - $78.44 $430,115 - $670,740
8,551 New
8,551 $671,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.77B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Brandywine Managers, LLC Portfolio

Follow Brandywine Managers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brandywine Managers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Brandywine Managers, LLC with notifications on news.